MediMix Oncology
  • Home
  • Congresses
    • 2026
      • ASCO GU 2026
      • ASCO GI 2026
    • 2025
      • SABCS 2025
      • SIOG 2025
      • ESMO 2025
      • WCLC 2025
      • ESMO GI 2025
      • ASCO 2025
      • EADO 2025
      • ELCC 2025
      • ENETS 2025
  • What’s new doc
    • Breast Cancer
    • GI Cancer
    • GU Cancer
    • Lung Cancer
  • Webinars
    • ESDO GI Cancer – ESMO 2025
  • Contact
  • Other specialties
    • Dermatology
    • Hematology
    • Respirology
  • SIGN UP
  • SIGN IN
    • Login
    • Account
ESMO 2025 - Other

KINETICS: secondary outcomes

20 November 2025

Presented by Prof Dr Timon Vandamme (University Hospital Antwerp, Belgium)

Prof Dr Timon van Damme, a digestive oncologist at the University Hospital of Antwerp, presented the secondary outcomes of the KINETICS study, a retrospective analysis of 310 patients with GEP-NETs treated with LAN in the first-line setting. Patients were stratified into two equal groups according to their Ki-67 proliferation index: 155 patients with Ki-67 ≤10% and 155 with Ki-67 >10%. Progression-free survival outcomes from this cohort were previously reported at ESMO-GI; the current presentation focused on OS, time to treatment discontinuation or death (TTD), and time to next treatment (TTNT).

The study addresses a clinically relevant evidence gap. Although LAN is widely used in the management of GEP-NETs, data regarding its effectiveness in patients with tumors exhibiting Ki-67 >10% remain limited. The present cohort includes the patient population most frequently treated with this somatostatin analogue, thereby offering insight into real-world outcomes in both lower- and higher-grade disease.

In the full cohort, median OS reached 93 months, indicating favourable long-term survival under LAN-based management. Median OS was not reached in either Ki-67 subgroup; to differentiate outcomes further, the investigators examined the first quartile (Q1) OS, defined as the time point at which 25% of patients had died. In the overall cohort, Q1 OS was 50 months. When stratified, Q1 OS was 67 months for patients with Ki-67 ≤10% and 39 months for those with Ki-67 >10%. Although the higher Ki-67 group showed shorter survival, outcomes remained clinically meaningful, and LAN appeared to be well tolerated across both subgroups.

Subgroup analyses confirmed Ki-67 as a significant factor influencing survival, consistent with established prognostic understanding. Nevertheless, the data indicate that LAN remains a viable and safe treatment option even for patients with moderately elevated tumour proliferation indices. Findings from TTD and TTNT analyses further supported this conclusion, revealing patterns consistent with the OS results.

References:

Walter T, et al. ESMO 2025; Abstract 1720P.

Back to ESMO 2025 OTHER

You may also be interested in:

ENGOT-en11/GOG-3053/KEYNOTE-B21

Geriatric oncology: from research to clinical practice

IMForte

Tags:

poster

Share Article

Website created by MediMix © 2026 - Privacy Policy

  • Home
  • Congresses
    • 2026
      • ASCO GU 2026
      • ASCO GI 2026
    • 2025
      • SABCS 2025
      • SIOG 2025
      • ESMO 2025
      • WCLC 2025
      • ESMO GI 2025
      • ASCO 2025
      • EADO 2025
      • ELCC 2025
      • ENETS 2025
  • What’s new doc
    • Breast Cancer
    • GI Cancer
    • GU Cancer
    • Lung Cancer
  • Webinars
    • ESDO GI Cancer – ESMO 2025
  • Contact
  • Other specialties
    • Dermatology
    • Hematology
    • Respirology
  • SIGN UP
  • SIGN IN
    • Login
    • Account
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.